Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females who are one year post-menopausal or without childbearing potential
Between the ages of 50 and 85 years old
Mild cognitive impairment confirmed by Mini Mental State Examination (MMSE) score between 23 and 27
Cooperative, able to ingest oral medication, and able to complete all aspects of the study and capable of doing so, either alone or with the aid of a responsible caregiver, according to the investigator's judgement
You may not be if
A current diagnosis of cerebrovascular disease, any primary neurodegenerative disorder, or any other causes of neuropsychologic disturbances or secondary dementia
A current diagnosis of epilepsy or depression, or any other diagnosis that may interfere with the patient's response to study medication
An advanced, severe or unstable disease of any type that may interfere with efficacy evaluations
Clareo Health | Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
